Last reviewed · How we verify
NCT05977257: VITAL
VitaFlow® Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up （VITAL）
trial testing VitaFlow® Transcatheter Aortic Valve Replacement System in Aortic Valve Disease in 89 participants. Not yet recruiting.
30 October 2025
Quick facts
| Lead sponsor | Shanghai MicroPort CardioFlow Medtech Co., Ltd. |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 89 |
| Start date | 30 July 2023 |
| Primary completion | 30 October 2025 |
| Estimated completion | 30 October 2028 |
| Sites | 4 locations across China |
Drugs / interventions tested
- VitaFlow® Transcatheter Aortic Valve Replacement System
Conditions studied
- Aortic Valve Disease — all drugs for Aortic Valve Disease →
- Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →
Sponsor
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Who can join
18 and older, any sex, with Aortic Valve Disease or Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an observational study to evaluate the long-term safety and effectiveness of the valve system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05977257
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Valve Disease
Currently open trials in the same condition.
- NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
- NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
- NCT07021612 — A Clinical and Imaging Registry of Transcatheter Aortic Valve Implantation Using JenaValve System/ J-Valve System for Pa · recruiting
- NCT06896227 — TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics · NA · recruiting
- NCT06189976 — Rapid Atrial Pacing After TAVI to Predict Pacemaker Implantation · NA · recruiting
Other Shanghai MicroPort CardioFlow Medtech Co., Ltd. trials
Trials by the same sponsor.
- NCT06597188 — TAVR vs. SAVR Study of VitaFlow Liberty® for Severe BAV Stenosis · NA · enrolling by invitation
- NCT07304427 — Alwide Plus China Post-market Clinical Investigation · completed
- NCT04414865 — VitaFlow™ Transcatheter Aortic Valve System Post-market Study-The LAUNCH Study · recruiting
- NCT04414878 — VitaFlow™ II Transcatheter Aortic Valve System Pre-market Trial · NA · recruiting
- NCT04655742 — VitaFlow™ Transcatheter Aortic Valve System Pre-market Trial · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05977257 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai MicroPort CardioFlow Medtech Co., Ltd.
- Last refreshed: 4 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05977257.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing